Geneva, Switzerland and Boston, MA – July 31, 2018– ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and…
Month: July 2018
ObsEva Expands Executive Team Hiring a Chief Commercial Officer
Geneva, Switzerland and Boston, MA – July 25, 2018– ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and…
ObsEva SA to start trading today on the SIX Swiss Exchange
Trading of ObsEva’s shares on SIX Swiss Exchange starts under the ticker symbol ‘OBSN’ Reference price at CHF 15.00 per share ObsEva with unique…
SIX Listing
Le Temps – La biotech genevoise ObsEva entre à la bourse suisse
24heures: Depuis Genève, ObsEva lutte contre l’infertilité
ObsEva SA Shares to Begin Trading on SIX Swiss Exchange
Listing of 45’381’252 registered shares with a par value of 1/13 of CHF 1 per share Anticipated market capitalisation of more…
Effects of the oral oxytocin receptor antagonist nolasiban on early embryonic development
O. Pohl, D. Perks, R. Sisti, J.P. Gotteland
ESHRE Annual Conference, 01-04 July 2018, Barcelona, Spain
Abstract P-121 on Pages i196-i197